S. Iacobelli, E. Combier, A. Roussot, J. Cottenet, J. Gouyon et al., Gestational age and 1-year hospital admission or mortality: a nation-wide population-based study, BMC Pediatr, vol.18, issue.1, p.28, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01476993

N. Townsi, I. A. Laing, G. L. Hall, and S. J. Simpson, The impact of respiratory viruses on lung health after preterm birth, Eur Clin Respir J, vol.5, issue.1, p.1487214, 2018.

X. Carbonell-estrany, E. G. Pérez-yarza, L. S. García, G. Cabañas, J. M. Bòria et al., Long-Term Burden and Respiratory Effects of Respiratory Syncytial Virus Hospitalization in Preterm Infants-The SPRING Study, PLoS ONE, vol.10, issue.5, p.125422, 2015.

. Palivizumab, humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group, Pediatrics. sept, vol.102, issue.3, pp.531-538, 1998.

A. Capizzi, M. Silvestri, A. Orsi, R. Cutrera, G. A. Rossi et al., The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence, Ital J Pediatr, vol.14, issue.2017

T. De and C. Pétriat, Evaluation des pratiques d'utilisation du Palivizumab (SYNAGIS®) en France. Implication des réseaux de santé en périnatalité, 2015.

H. Torchin, P. Ancel, P. Jarreau, and F. Goffinet,

, J Gynecol Obstet Biol Reprod

R. Gouyon-j-b, G. , and G. Adamon-l,

D. I. Maio-m, Hospitalizations for respiratory syncytial virus bronchiolitis in preterm infants at <33 weeks gestation without bronchopulmonary dysplasia: the CASTOR study, Epidemiol Infect. avr, vol.141, issue.4, pp.816-842, 2013.

P. Haataja, P. Korhonen, R. Ojala, M. Hirvonen, M. Korppi et al., Hospital admissions for lower respiratory tract infections in children born moderately/late preterm, Pediatr Pulmonol. févr, vol.53, issue.2, pp.209-226, 2018.

M. Delnord and J. Zeitlin, Epidemiology of late preterm and early term births -An international perspective, Semin Fetal Neonatal Med, vol.18, 2018.

H. Torchin, J. Rousseau, L. Marchand-martin, P. Truffert, P. Jarreau et al., Palivizumab administration in preterm infants in France: EPIPAGE-2 cohort study, Arch Pediatr. févr, vol.25, issue.2, pp.89-94, 2018.

D. Dixon, The Role of Human Milk Immunomodulators in Protecting Against Viral Bronchiolitis and Development of Chronic Wheezing Illness, Children (Basel). 7 juill, vol.2, issue.3, pp.289-304, 2015.

Z. Stra?ák, E. Saliba, P. Kosma, K. Posfay-barbe, K. Yunis et al., Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI), PLoS ONE, vol.11, issue.6, p.157446, 2016.

J. Mauskopf, A. V. Margulis, M. Samuel, and K. N. Lohr, Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review, Pediatr Infect Dis J, vol.35, issue.7, pp.229-238, 2016.

B. Resch, Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection, Hum Vaccin Immunother, vol.02, issue.9, p.42, 2017.

K. Korsten, M. O. Blanken, B. Buiteman, E. E. Nibbelke, C. A. Naaktgeboren et al.,

S. Yoshihara, S. Kusuda, H. Mochizuki, K. Okada, S. Nishima et al., Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants, Pediatrics. nov, vol.132, issue.5, pp.811-819, 2013.